Recurrence-Free Survival in Early and Locally Advanced Large Cell Neuroendocrine Carcinoma of the Lung after Complete Tumor Resection

被引：4

作者：

Altieri, Barbara ^{[1
]}

La Salvia, Anna ^{[2
]}

Modica, Roberta ^{[3
]}

Marciello, Francesca ^{[3
]}

Mercier, Olaf ^{[4
]}

Filosso, Pier Luigi ^{[5
]}

de Latour, Bertrand Richard ^{[6
]}

Giuffrida, Dario ^{[7
]}

Campione, Severo ^{[8
]}

Guggino, Gianluca ^{[9
]}

Fadel, Elie ^{[4
]}

Papotti, Mauro ^{[10
]}

Colao, Annamaria ^{[3
]}

Scoazec, Jean-Yves ^{[11
]}

Baudin, Eric ^{[12
]}

Faggiano, Antongiulio ^{[13
]}

机构：

[1] Univ Wurzburg, Univ Hosp, Dept Internal Med1, Div Endocrinol & Diabet, D-97080 Wurzburg, Germany

[2] Natl Inst Hlth ISS, Natl Ctr Drug Res & Evaluat, I-00161 Rome, Italy

[3] Univ Naples Federico II, Dept Clin Med & Surg, I-80131 Naples, Italy

[4] Univ Paris Saclay, Marie Lannelongue Hosp, Dept Thorac Surg & Heart & Lung Transplantat, GHPSJ, F-92350 Le Plessis Robinson, France

[5] Univ Turin, San Giovanni Battista Hosp, Dept Thorac Surg, I-10126 Turin, Italy

[6] Univ Rennes, Univ Hosp Rennes Pontchaillou, Dept Thorac & Cardiovasc Surg, Rennes, France

[7] Mediterranean Inst Oncol, Dept Expt Oncol, Clin Oncol Unit, I-95029 Catania, Italy

[8] Cardarelli Hosp, Dept Adv Technol, Pathol Unit, I-80131 Naples, Italy

[9] Cardarelli Hosp, Dept Thorac Surg, I-80131 Naples, Italy

[10] Univ Turin, Dept Oncol, Pathol Unit, I-10126 Turin, Italy

[11] Univ Paris Saclay, Inst Gustave Roussy, Dept Pathol, F-94805 Villejuif, France

[12] Paris Saclay Univ, Inst Gustave Roussy, Endocrine Oncol & Nucl Med Dept, F-94805 Villejuif, Paris, France

[13] Sapienza Univ Rome, Sant Andrea Hosp, Dept Clin & Mol Med, Endocrinol Unit, I-00189 Rome, Italy

来源：

JOURNAL OF PERSONALIZED MEDICINE | 2023年 / 13卷 / 02期

关键词：

neuroendocrine tumor; LCNEC; pulmonary cancer; prognostic marker; prognosis; survival; lymph nodes; age; surgery; adjuvant therapy; CLASSIFICATION; EPIDEMIOLOGY; OUTCOMES; SURGERY; CANCER;

D O I：

10.3390/jpm13020330

中图分类号：

R19 [保健组织与事业（卫生事业管理）];

学科分类号：

摘要：

Background: Large Cell Neuroendocrine Carcinoma (LCNEC) is a rare subtype of lung cancer with poor clinical outcomes. Data on recurrence-free survival (RFS) in early and locally advanced pure LCNEC after complete resection (R0) are lacking. This study aims to evaluate clinical outcomes in this subgroup of patients and to identify potential prognostic markers. Methods: Retrospective multicenter study including patients with pure LCNEC stage I-III and R0 resection. Clinicopathological characteristics, RFS, and disease-specific survival (DSS) were evaluated. Univariate and multivariate analyses were performed. Results: 39 patients (M:F = 26:13), with a median age of 64 years (44-83), were included. Lobectomy (69.2%), bilobectomy (5.1%), pneumonectomy (18%), and wedge resection (7.7%) were performed mostly associated with lymphadenectomy. Adjuvant therapy included platinum-based chemotherapy and/or radiotherapy in 58.9% of cases. After a median follow-up of 44 (4-169) months, the median RFS was 39 months with 1-, 2- and 5-year RFS rates of 60.0%, 54.6%, and 44.9%, respectively. Median DSS was 72 months with a 1-, 2- and 5-year rate of 86.8, 75.9, and 57.4%, respectively. At multivariate analysis, age (cut-off 65 years old) and pN status were independent prognostic factors for both RFS (HR = 4.19, 95%CI = 1.46-12.07, p = 0.008 and HR = 13.56, 95%CI 2.45-74.89, p = 0.003, respectively) and DSS (HR = 9.30, 95%CI 2.23-38.83, p = 0.002 and HR = 11.88, 95%CI 2.28-61.84, p = 0.003, respectively). Conclusion: After R0 resection of LCNEC, half of the patients recurred mostly within the first two years of follow-up. Age and lymph node metastasis could help to stratify patients for adjuvant therapy.

引用

页数：14